clinical trial · NCT03643107
Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®)
Metastatic Castration-Resistant Prostate Cancer PatientsIrofulvenPrednisolone 10 mg
brief summary
The study seek to evaluate the anti-tumor effect after treatment of Irofulven in combination with prednisolone in patients who progressed on androgen receptor(AR)-targeted therapy and Docetaxel-Pretreated Metastatic Castration-Resistant Prostate Cancer Patients. A drug response predictor (DRP®) biomarker in prostate cancer patients will identify patients likely to respond to and benefit from treatment with Irofulven.
started
Oct 17, 2018
primary completion
Oct 1, 2021
completion
Aug 1, 2022
last updated
Jan 23, 2025
official title
Phase II Study of Irofulven in AR-targeted and Docetaxel-Pretreated Metastatic Castration-Resistant Prostate Cancer Patients, Who Have a Drug Response Predictor (DRP®) Indicating a High Likelihood of Response to Irofulven.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol